Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Non-Current Deffered Revenue (2016 - 2017)

Arcadia Biosciences (RKDA) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $2.0 million as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Non-Current Deffered Revenue fell 34.68% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Dec 2017, down 34.68%, and an annual FY2017 reading of $2.0 million, down 34.68% over the prior year.
  • Non-Current Deffered Revenue was $2.0 million for Q4 2017 at Arcadia Biosciences, down from $2.8 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $3.6 million in Q4 2014 and bottomed at $2.0 million in Q4 2017.
  • Average Non-Current Deffered Revenue over 4 years is $2.8 million, with a median of $2.8 million recorded in 2017.
  • Peak annual rise in Non-Current Deffered Revenue hit 28.44% in 2017, while the deepest fall reached 34.68% in 2017.
  • Year by year, Non-Current Deffered Revenue stood at $3.6 million in 2014, then dropped by 27.48% to $2.6 million in 2015, then grew by 18.32% to $3.1 million in 2016, then crashed by 34.68% to $2.0 million in 2017.
  • Business Quant data shows Non-Current Deffered Revenue for RKDA at $2.0 million in Q4 2017, $2.8 million in Q3 2017, and $2.9 million in Q2 2017.